GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Question] how do you actually verify glucagon — 18 comments in the full submission. View in context.
354
c/survodutide·submitted 1 months ago by u/tuva_kirchner

[Question] how do you actually verify glucagon

Questionbranch of 9 comments

Quick one. Canada here. MASH works very differently where I live than in the threads that dominate the front page, and I keep seeing people confidently given advice that simply does not apply outside the US. Specifics: the route I used took 24 weeks and cost roughly what I expected. The admin was worse than the cost.…

Read the full submission and all 18 comments →

This branch

9 comments, started 1 months ago
u/dexa_twice_yearlybody comp43 points·1 months ago

Titration speed is a side-effect dial far more than an efficacy dial.

replysharereportpermalink
u/marisol_frisk27 points·1 months ago

the safety profile is not just tirzepatide amplified

replysharereportpermalink
u/renzo_yildiz11 points·1 months ago

hepatic fat and survodutide are the story

replysharereportpermalink
u/meera_sandvik14 points·1 months ago

Strongly agree. The safety story is separate.

replysharereportpermalink
u/rania_salinas11 points·1 months ago

glucagon injection is a different vector than GLP-1

replysharereportpermalink
u/injection_site_iris8 points·1 months ago

glucagon co-agonism has a different safety story

replysharereportpermalink
u/endotoxin_elliemicro6 points·1 months ago

glucagon injection is a different vector than GLP-1

replysharereportpermalink
u/chidi_demir17 points·1 months ago

This is correct. Do not generalise from tirzepatide.

replysharereportpermalink
u/tuva_kirchnerOP10 points·1 months ago

glucagon injection is a different vector than GLP-1

replysharereportpermalink

← back to the whole thread

About c/survodutide

Survodutide-specific discussion: glucagon-receptor co-agonism, the hepatic fat and MASH resolution data, and how the side-effect profile compares with GIP-based dual agonism. Small community, high signal.

12kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
More in c/survodutide
c/survodutide rules
  1. Glucagon co-agonism has a distinct safety story. Do not generalise from tirzepatide.
  2. MASH claims need the trial and the biopsy endpoint.
  3. Not approved. Descriptive posts only.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/incretin_ivyu/liver_enzyme_lizu/trialwatch_theo
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →